The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
The Drugs Don't Work: Expectations and the Shaping of Pharmacogenetics
Abstract
This article examines one particular set of technologies arising from developments in human genetics, those aimed at improving the targeting, design and use of conventional small molecule drugs - pharmacogenetics. Much of the debate about the applications and consequences of pharmacogenetics has been highly speculative, since little or no working technology is yet on the market. This article provides a novel analysis of the development of pharmacogenetics, and the social and ethical issues it raises, based on the sociology of technological expectations. In particular, it outlines how two alternative visions for the development of the technology are being articulated and embedded in a range of heterogeneous discourses, artefacts, actor strategies and practices, including: competing scientific research agendas, experimental technologies, emerging industrial structures and new ethical discourses. Expectations of how pharmacogenetics might emerge in each of these arenas are actively shaping the trajectory of this nascent technology and its potential socio-economic consequences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pinch, T. J., & Bijker, W. E. (1984) · Social Studies of Science · doi:10.1177/030631284014003004 · Cited by 3,890
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
Evans, W. E., & Relling, M. V. (1999) · Science · doi:10.1126/science.286.5439.487 · Cited by 2,475
Society in the making: The study of technology as a tool for sociological analysis
Callon, M. (1987) · VTechWorks (Virginia Tech) · Cited by 998
Pharmacogenetics and the practice of medicine
Roses, A. D. (2000) · Nature · doi:10.1038/35015728 · Cited by 810
Characterization of the common genetic defect in humans deficient in debrisoquine metabolism
Gonzalez, F. J., Skodat, R. C., Kimura, S., Umeno, M., Zanger, U. M., Nebert, D. W., Gelboin, H. V., Hardwick, J. P., & Meyer, U. A. (1988) · Nature · doi:10.1038/331442a0 · Cited by 715
Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions: A Systematic Review
Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K., & Sadee, W. (2001) · JAMA · doi:10.1001/jama.286.18.2270 · Cited by 705
Kuivenhoven, J. A., Jukema, J. W., Zwinderman, A. H., de Knijff, P., McPherson, R., Bruschke, A. V. G., Lie, K. I., & Kastelein, J. J. P. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380203 · Cited by 625
Pharmacogenetics and adverse drug reactions
Meyer, U. A. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03167-6 · Cited by 602
Poirier, J., Delisle, M. C., Quirion, R., Aubert, I., Farlow, M., Lahiri, D., Hui, S., Bertrand, P., Nalbantoglu, J., & Gilfix, B. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.26.12260 · Cited by 595
Drazen, J. M., Yandava, C. N., Dubé, L., Szczerback, N., Hippensteel, R., Pillari, A., Israel, E., Schork, N., Silverman, E. S., Katz, D. A., et al. (1999) · Nature Genetics · doi:10.1038/9680 · Cited by 560
Personalized medicine: revolutionizing drug discovery and patient care
Ginsburg, G. (2001) · Trends in Biotechnology · doi:10.1016/s0167-7799(01)01814-5 · Cited by 456
Pharmacogenetic prediction of clozapine response
Arranz, M., Munro, J., Birkett, J., Bolonna, A., Mancama, D., Sodhi, M., Lesch, K., Meyer, J., Sham, P., Collier, D., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02221-2 · Cited by 347
Pharmacogenomics: Unlocking the Human Genome for Better Drug Therapy
McLeod, H. L., & Evans, W. E. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.101 · Cited by 331
Science, medicine, and the future: Pharmacogenetics
Wolf, C. R. (2000) · BMJ · doi:10.1136/bmj.320.7240.987 · Cited by 288
Pharmacogenomics: The promise of personalized medicine
Mancinelli, L., Cronin, M., & Sadée, W. (2000) · AAPS PharmSci · doi:10.1208/ps020104 · Cited by 267
Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy
Ingelman‐Sundberg, M. (2001) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2001.00879.x · Cited by 242
The Rise of Membrane Technology: From Rhetorics to Social Reality
van Lente, H., & Rip, A. (1998) · Social Studies of Science · doi:10.1177/030631298028002002 · Cited by 235
The new genetics: The new genetics in clinical practice
Bell, J. (1998) · BMJ · doi:10.1136/bmj.316.7131.618 · Cited by 214
The new genetics and clinical practice
Weatherall, D. J. (1982) · Andalas University Repository (Andalas University) · Cited by 175
Genome-based pharmacogenetics and the pharmaceutical industry
Roses, A. D. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd840 · Cited by 168
Impact of genomics on drug discovery and clinical medicine
Emilien, G., Ponchon, M., Caldas, C., Isacson, O., & Maloteaux, J. M. (2000) · QJM · doi:10.1093/qjmed/93.7.391 · Cited by 165
Vision Assessment: Shaping Technology in 21st Century Society
(2000) · Springer eBooks · doi:10.1007/978-3-642-59702-2 · Cited by 159
Krynetski, E. Y., & Evans, W. E. (1999) · Pharmaceutical Research · doi:10.1023/a:1011909315614 · Cited by 136
Ethical perspectives on pharmacogenomic profiling in the drug development process
Issa, A. (2002) · Nature reviews. Drug discovery · doi:10.1038/nrd771 · Cited by 119
Ensom, M. H. H., Chang, T. K. H., & Patel, P. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140110-00001 · Cited by 119
Privacy and Confidentiality of Genetic Information: What Rules for the New Science?
Anderlik, M. R., & Rothstein, M. A. (2001) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.2.1.401 · Cited by 111
Hughes, G. F., & Fitzharris, P. (1999) · BMJ · doi:10.1136/bmj.319.7201.1 · Cited by 107
Designing the future: the culture of new trends in science and technology
Guice, J. (1999) · Research Policy · doi:10.1016/s0048-7333(98)00105-x · Cited by 102
Pharmacogenetic applications of the Human Genome project
Liggett, S. B. (2001) · Nature Medicine · doi:10.1038/85411 · Cited by 94
Clinical trials in pharmacogenetics and pharmacogenomics: Methods and applications
Rioux, P. P. (2000) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/57.9.887 · Cited by 87
Pharmacogenomics: A Clinician's Primer on Emerging Technologies for Improved Patient Care
Rusnak, J. M., Kisabeth, R. M., Herbert, D. P., & McNeil, D. M. (2001) · Mayo Clinic Proceedings · doi:10.4065/76.3.299 · Cited by 85
Terminology and the Construction of Scientific Disciplines: The Case of Pharmacogenomics
Hedgecoe, A. M. (2003) · Science Technology & Human Values · doi:10.1177/0162243903256274 · Cited by 84
Self-citationGetting the right drug into the right patient
Marshall, A. (1997) · Nature Biotechnology · doi:10.1038/nbt1197-1249 · Cited by 81
Corrigan, O. (2002) · Social Science & Medicine · doi:10.1016/s0277-9536(01)00183-6 · Cited by 81
Ethical considerations in clinical pharmacogenomics research
Issa, A. M. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01493-0 · Cited by 81
Pharmacogenetic screening and therapeutic drugs
Steimer, W., & Potter, J. M. (2002) · Clinica Chimica Acta · doi:10.1016/s0009-8981(01)00713-6 · Cited by 78
Reinventing diabetes: Classification, division and the geneticization of disease
Hedgecoe, A. M. (2002) · New Genetics and Society · doi:10.1080/14636770220122746 · Cited by 77
Self-citationTesting drug response in the presence of genetic information: sampling issues for clinical trials
Cardon, L. R., Idury, R. M., Harris, T., Witte, J. S., & Elston, R. C. (2000) · Pharmacogenetics · doi:10.1097/00008571-200008000-00003 · Cited by 75
A SNPshot: pharmacogenetics and the future of drug therapy
Pfost, D. R., Boyce-Jacino, M. T., & Grant, D. M. (2000) · Trends in biotechnology · doi:10.1016/s0167-7799(00)01463-3 · Cited by 69
(2001) · Edward Elgar Publishing eBooks · doi:10.4337/9781843762867 · Cited by 55
Principles, organization, and operation of a DNA bank for clinical trials:
Lavori, P. W., Krause-Steinrauf, H. J., Brophy, M. T., Buxbaum, J. N., Cockroft, J., Cox, D., Fiore, L. D., Greely, H. T., Greenberg, H. B., Holmes, E. W., et al. (2002) · Controlled Clinical Trials · doi:10.1016/s0197-2456(02)00193-9 · Cited by 49
Pharmacogenomics: will it change the field of medicine?
Wieczorek, S. J., & Tsongalis, G. J. (2001) · Clinica Chimica Acta · doi:10.1016/s0009-8981(01)00419-3 · Cited by 48
Elliott, C. (2001) · PubMed · Cited by 43
Exploiting human genetic variation in drug discovery and development
Jazwinska, E. C. (2001) · Drug Discovery Today · doi:10.1016/s1359-6446(00)01642-1 · Cited by 36
Molecular genetics and the future of pharmacogenetics
Meyers, U. A. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90023-u · Cited by 35
Pharmacogenomics: out of the lab and into the community
Nebert, D. W. (2001) · Trends in biotechnology · doi:10.1016/s0167-7799(01)01805-4 · Cited by 32
Issa, A. M., & Keyserlingk, E. W. (2000) · The Canadian Journal of Psychiatry · doi:10.1177/070674370004501007 · Cited by 32
Pharmacogenetics, Race, and Ethnicity: Social Identities and Individualized Medical Care
Foster, M. W., Sharp, R. R., & Mulvihill, J. J. (2001) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200106000-00009 · Cited by 31
The legacy of pharmacogenetics and potential applications
Weber, W. W. (2001) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(01)00151-8 · Cited by 30
Pharmacogenetics: the ethical context
Thomas, S. M. (2001) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500052 · Cited by 30
Opportunities and strategies for introducing pharmacogenetics into early drug development
Chamberlain, J., & Joubert, P. (2001) · Drug Discovery Today · doi:10.1016/s1359-6446(01)01777-9 · Cited by 25
Pharmacogenetics in clinical dermatology: TOPICAL REVIEW
Ameen, M., Smith, C. H., & Barker, J. N. (2002) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2002.04466.x · Cited by 23
Introduction: the Sociology of Medical Science and Technology
Elston, M. A. (1997) · Sociology of Health & Illness · doi:10.1111/1467-9566.00084 · Cited by 17
Genomics and medicine: an anticipation.
Kaplan, J., & Junien, C. (2000) · Comptes Rendus de l Académie des Sciences - Series III - Sciences de la Vie · doi:10.1016/s0764-4469(00)01252-x · Cited by 17
Pharmacogenetics: theRx perspective
Renegar, G., Rieser, P. A., & Manasco, P. K. (2001) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.1.3.255 · Cited by 15
Jc, K. (2000) · Comptes Rendus Biologies · Cited by 13
Carroll, A. M., & Coleman, C. H. (2001) · Genetic Testing · doi:10.1089/109065701753617390 · Cited by 7
Cited by
Developing a framework for responsible innovation
Stilgoe, J., Owen, R., & Macnaghten, P. (2013) · Research Policy · doi:10.1016/j.respol.2013.05.008 · Cited by 3,184
Jasanoff, S., & Kim, S.-H. (2009) · Minerva · doi:10.1007/s11024-009-9124-4 · Cited by 1,911
The sociology of expectations in science and technology
Borup, M., Brown, N., Konrad, K., & Van Lente, H. (2006) · Technology Analysis & Strategic Management · doi:10.1080/09537320600777002 · Cited by 1,902
What is an emerging technology?
Rotolo, D., Hicks, D., & Martin, B. R. (2015) · Research Policy · doi:10.1016/j.respol.2015.06.006 · Cited by 1,356
Evaluating meta-ethnography: systematic analysis and synthesis of qualitative research
Campbell, R., Pound, P., Morgan, M., Daker-White, G., Britten, N., Pill, R., Yardley, L., Pope, C., & Donovan, J. (2011) · Health Technology Assessment · doi:10.3310/hta15430 · Cited by 619
Metadata
- Authors
- Hedgecoe, A., & Martin, P.
- Venue
- Social Studies of Science
- Publisher
- SAGE Publications
- Published
- 2003-06
- Volume
- 33
- Issue
- 3
- Pages
- 327-364
- ISSN
- 0036-8539 (ISSN-L)
- 0306-3127
- 1460-3659
- OpenAlex
- W2151144872
- Cited by
- 340
- References
- 58
- FWCI
- 11.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.